M Ventures is the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany, investing in Biotechnology and Technology. It invests globally in transformational ideas across healthcare, life science, and electronics from its headquarters in Amsterdam.
33% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $35.8M (across 141 rounds with reported amounts).
Portfolio
139
Fund Size
$677M
Top Stage
Series A
Last 12 Mo
12
Team
Vijay Narasimhan
Director of Technology Investments and Partnerships
Emma Johnson
Senior Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
202 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Remepy | Series A | $36M | Aug 2026 |
 Cyllene | Series C | — | Jul 2026 |
 Storm Therapeutics | Series C | $56M | Apr 2026 |
 Gency AI | Series B | $20M | Mar 2026 |
 Theolytics | Unknown | — | Mar 2026 |
 Consio AI | Seed | $3.3M | Jan 2026 |
| CConsio | Seed | $3.3M | Jan 2026 |
 Vizgen | Series C | $48M | Jan 2026 |
 Lightcast | Unknown | $27M | Jan 2026 |
 FoRx Therapeutics | Series A | $50M | Dec 2025 |
 NovoLINC | Unknown | — | Dec 2025 |
 Artios | Series D | $115M | Nov 2025 |
 FMC | Series C | — | Nov 2025 |
 NRG Therapeutics | Series B | $50M | Sep 2025 |
 Actithera | Series A | $75.5M | Jul 2025 |
 ReproNovo | Series A | $65M | May 2025 |
 Stimuler | Seed | $3.8M | Apr 2025 |
 Forge Nano | Unknown | $40M | Apr 2025 |
 ChEmpower | Series A | $18.7M | Apr 2025 |
 Corvic | Seed | $12M | Apr 2025 |
| CCorvic AI | Seed | $12M | Apr 2025 |
 MemryX | Series B | $44M | Mar 2025 |
 TRIMTECH Therapeutics | Seed | $14M | Mar 2025 |
| HHD | Unknown | $7.8M | Feb 2025 |
| NovoLINC | Seed | — | Jan 2025 |
Page 1 of 9
Top Co-Investors
Merck21 shared
Sofinnova Partners21 shared
Pfizer Ventures21 shared
SV Health Investors13 shared
Andera Partners12 shared
Novartis Venture Fund11 shared
EQT Life Sciences10 shared
IP Group plc10 shared
INKEF Capital10 shared
Illumina Ventures9 shared
Omega Funds9 shared
3M Ventures8 shared
Schroders Capital8 shared
Foothill Ventures8 shared
Alexandria Venture Investments7 shared
RA Capital Management7 shared
Novartis Pharma AG7 shared
ARCH Venture Partners7 shared
Octopus Ventures6 shared
Bpifrance6 shared
Last updated: 20 October 2026